DaPeCa-7: comparative assessment of fluorodeoxyglucose positron emission tomography/computed tomography (CT) and conventional diagnostic CT in diagnosis of lymph node metastases, distant metastases and incidental findings in patients with invasive penile cancer

Uro-Oncology

Utility of Routine Preoperative ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (¹⁸F-FDG PET/CT) in Identifying Pathologic Lymph Node Metastases at Radical Cystectomy

J Urol.

Dason S, Wong NC, Donahue TF, Meier A, Zheng J, Mannelli L, Di Paolo PL, Dean LW, McPherson VA, Rosenberg JE, Bajorin DF, Capeanu M, Dalbagni G, Vargas HA, Bochner BH

doi: 10.1097/JU.0000000000001006.

Uro-Oncology

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

J Urol.

Bach-Gansmo T, Nanni C, Nieh PT, Zanoni L, Bogsrud TV, Sletten H, Korsan KA, Kieboom J, Tade FI, Odewole O, Chau A, Ward P, Goodman MM, Fanti S, Schuster DM, Willoch F

doi: 10.1016/j.juro.2016.09.117.

Uro-Oncology

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy

Eur Urol.

Rauscher I, Düwel C, Haller B, Rischpler C, Heck MM, Gschwend JE, Schwaiger M, Maurer T, Eiber M

doi: 10.1016/j.eururo.2018.01.006.

Uro-Oncology

Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series

Eur Urol.

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A

doi: 10.1016/j.eururo.2020.06.047.

Uro-Oncology

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection

Eur Urol.

Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, Borgmann H, Heidegger I, Steinkohl F, Kretschmer A, Marra G, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, Den Bergh RV, Ost P, Gontero P, Montorsi F, Briganti A, EAU-YAU Prostate Cancer Working Group

doi: 10.1016/j.eururo.2020.03.023.

Uro-Oncology

Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer

BJU Int.

Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Mazzone E, Dell'Oglio P, Stabile A, Freschi M, Montorsi F, Briganti A

doi: 10.1111/bju.14066.

Uro-Oncology

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought

Eur Urol.

Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, Briganti A

doi: 10.1016/j.eururo.2020.06.043.

Uro-Oncology

KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy

Prostate Cancer Prostatic Dis.

Lunger L, Retz M, Bandur M, Souchay M, Vitzthum E, Jäger M, Weirich G, Schuster T, Autenrieth M, Kübler H, Maurer T, Thalgott M, Herkommer K, Koll F, Gschwend JE, Nawroth R, Heck MM

doi: 10.1038/s41391-020-00283-3.

Uro-Oncology

Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis

J Urol.

Crocerossa F, Marchioni M, Novara G, Carbonara U, Ferro M, Russo GI, Porpiglia F, Di Nicola M, Damiano R, Autorino R, Cantiello F

doi: 10.1097/JU.0000000000001369.

Related content

Utility of Routine Preoperative 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET/CT) in Identifying Pathologic Lymph Node Metastases at Radical Cystectomy

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.

Efficacy, Predictive Factors, and Prediction Nomograms for 68Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy

Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection

Identifying the candidate for super extended staging pelvic lymph node dissection among patients with high-risk prostate cancer

Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought

KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy

Detection Rate of Prostate-Specific Membrane Antigen Tracers for Positron Emission Tomography/Computed Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis

Utility of Routine Preoperative ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (¹⁸F-FDG PET/CT) in Identifying Pathologic Lymph Node Metastases at Radical Cystectomy

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer.